Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026
Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026
Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026
Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate

Fineline Cube Sep 13, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...

Company Drug

CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials

Fineline Cube Sep 13, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials

Fineline Cube Sep 13, 2022

Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from...

Drug

China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021

Fineline Cube Sep 9, 2022

According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...

Medical Device Policy / Regulatory

National High-Value Medical Consumables VBP Round Targets Orthopedic Spine Products

Fineline Cube Sep 9, 2022

The national high-value medical consumables joint procurement office released a set of guiding opinions on...

Company Drug

China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study

Fineline Cube Sep 9, 2022

Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the...

Company Drug

Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial

Fineline Cube Sep 9, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...

Company Policy / Regulatory

MofCOM’s 2021 Pharma Distribution Report Shows Market Recovery

Fineline Cube Sep 9, 2022

The Ministry of Commerce (MofCOM) released its annual statistical review of the pharma distribution industry...

Policy / Regulatory

NHSA Issues Notice on Special Treatment of Oral Implant Medical Service Charges

Fineline Cube Sep 9, 2022

The National Healthcare Security Administration (NHSA) has released a Notice on “Carrying out Special Treatment...

Company Drug

Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Sep 9, 2022

The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...

Company Deals Digital

Realcan Pharma and AWS Expand Partnership for Digital Transformation

Fineline Cube Sep 9, 2022

China-based Realcan Pharmaceutical Group Co., Ltd (SHE: 002589) and Amazon Web Services (AWS) have agreed...

Company Legal / IP

Salipro Biotech Secures Patent Protection for Membrane Protein Stabilization Tech

Fineline Cube Sep 9, 2022

Sweden-based Salipro Biotech AB announced that its core technology for stabilizing membrane proteins for drug...

Company Drug

Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction

Fineline Cube Sep 8, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in...

Company

China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth

Fineline Cube Sep 8, 2022

A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...

Company Deals

Suzhou InnoBM Pharmaceuticals Raises Series A+ Funding for Tumor Immunotherapy

Fineline Cube Sep 8, 2022

China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+...

Company Drug

Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer

Fineline Cube Sep 8, 2022

China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in...

Policy / Regulatory

NHSA Reveals Drugs Passing Initial Review for NRDL Inclusion

Fineline Cube Sep 8, 2022

The National Healthcare Security Administration (NHSA) released a notification listing the drugs that have passed...

Company Drug

Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC

Fineline Cube Sep 8, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced positive results from the Phase III ORIENT-31 study...

Company Deals

Huadong Medicine Pays EUR 105M for 35% Stake in Heidelberg Pharma

Fineline Cube Sep 8, 2022

China’s Huadong Medicine Co., Ltd (SHE: 000963) announced that it has paid a total of...

Company Deals

CStone Pharmaceuticals Partners with Rigen Biotech on Thyroid Cancer RET Gene Testing

Fineline Cube Sep 8, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has entered into a partnership with Shanghai Rigen Biotech to...

Posts pagination

1 … 666 667 668 … 706

Recent updates

  • China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
  • Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
  • Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
  • Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
  • Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.